You are here

An epitope-focused nanoparticle vaccine for anthrax

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44AI142939-02
Agency Tracking Number: R44AI142939
Amount: $998,145.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-574
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-06-01
Award End Date (Contract End Date): 2022-05-31
Small Business Information
San Diego, CA 92109-5757
United States
DUNS: 160242579
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 581-3861
Business Contact
Phone: (858) 581-3960
Research Institution

We have successfully developed a highly immunogenic, optimized and lyophilizable epitope-focused, bivalent
anthrax vaccine, referred to as LND-LF-VLP, using our novel proprietary platform technology which
incorporates the vaccine target sequence into highly immunogenic virus like particles. This new vaccine targets
two distinct neutralizing determinants, which are not targeted by Biothrax, the currently approved vaccine for
anthrax. When formulated with human use adjuvants, this new vaccine has potential to elicit very rapid
protective immunity with only one or two injections. Our proposal will focus on two overarching aims: 1) to
demonstrate the efficacy of two immunizations with the LND-LF-VLP in human use adjuvants for protection of
rabbits from high dose aerosol spore challenge with Bacillus anthracis Ames strain and 2) to optimize and
develop standard operating procedures for the expression, purification and quality assurance of the LND-LF-
VLP vaccine in a manner enabling eventual scale-up production by a contract manufacturing organization. This
new epitope-focused, VLP vaccine promises to be a highly stable, safe and strategic new vaccine for anthrax.Spores of B. anthracis, the causative agent of anthrax, can be weaponized and represent a
threat to our armed forces and civilians at large. We are developing a new highly potent
vaccine for anthrax that will be a valuable addition to the immunopreventatives in the
Strategic National stockpile

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government